RSI Alert: Tempus AI (TEM) Now Oversold

Tempus AI (TEM) shares traded as low as $52.02 and registered an RSI of 29.8 on Wednesday, placing the stock in oversold territory versus the S&P 500 ETF (SPY) RSI of 51.6. The stock’s last trade was $52.14 within a 52-week range of $36.22 to $104.32, and the technical read suggests recent selling pressure may be exhausting, potentially presenting tactical buy-entry opportunities for investors focused on technical setups.

Analysis

Market structure: TEM’s RSI <30 signals technical exhaustion rather than fundamental victory; short-term beneficiaries are nimble long-biased quant funds and options sellers collecting premium, while late-stage private genomic/AI peers (high cash burn names) face capital pressure. Competitive dynamics: if sell-off is idiosyncratic, TEM can recapture share vs smaller clinical-data rivals by extending enterprise contracts — but sustained weakness would hand pricing leverage to larger cloud/AI incumbents (MSFT, GOOG) who can bundle analytics. Cross-asset: a TEM idiosyncratic drop will have negligible bond/FX impact but will raise single-name put flows and push short-dated IV higher; expect 10–30% IV spike in near-dated options if it tests $45 support.

Risk assessment: tail risks include regulatory data/privacy enforcement or a major HIPAA breach (low prob, high impact — >50% drawdown possible) and cash runway misses (quarterly burn shocks). Immediate (days): technical bounce or continuation; short-term (weeks–months): earnings/partnership catalysts decide direction; long-term (quarters–years): revenue cadence and payer adoption determine valuation re-rating. Hidden dependencies: enterprise sales cycles, reimbursement approvals, and model certification timelines; losing a marquee hospital client can reduce ARR growth by 10–30%. Key catalysts: quarterly results, material AI product FDA/partnership news, or insider/institutional buying within 30–90 days.

Trade implications: establish a tactical, size-limited exposure: small long exposure with strict stops, or defined-risk options to capture mean reversion. Pair trade: long TEM vs short ARKG/ARKK to isolate company recovery from sector rotation. Options: prefer debit call spreads or short put credit spreads to limit capital at risk while benefiting from RSI mean reversion and potential IV normalization.

Contrarian angles: consensus treats RSI dip as buy-the-dip; missing is balance-sheet and contract-closing risk — rebound may be limited absent pipeline clarity. Reaction could be overdone if liquidity-driven selling rather than fundamentals drove price; historically similar post-IPO AI-health sell-offs see 30–70% rebounds only after 2–4 quarters of execution. Unintended consequence: buying now without confirming ARR/contract data risks being trapped if negative guidance follows.

Key Decisions for Investors

• Consider establishing a 2% portfolio long position in TEM (buy $48–52) with a stop-loss at $36 (just below the 52-week low $36.22) and initial target of $75 over 3–9 months (risk/reward ~2.5x).
• If seeking defined risk, buy a 4–6 month TEM call spread (e.g., buy Jul 2026 $50 call, sell Jul 2026 $80 call) sized to 1% of portfolio; exit or roll if TEM closes >$70 for two consecutive weeks or IV rises >40%.
• Execute a pair trade: go long TEM (1.5% portfolio) and short ARKG (0.75% portfolio) to hedge sector risk; rebalance after 30–60 days or if TEM reports incremental enterprise contracts.
• If willing to own at lower cost, sell a cash-secured put spread: sell TEM $40/$35 put spread expiring in 60–90 days for net credit (max assignment risk owning TEM at $40); allocate no more than 1% capital.
• Reduce exposure to high-valuation AI/biotech momentum names by 2–4% and rotate into selective deep-value AI-in-health names (TEM, TELA-sized names) only after confirming quarterly ARR growth or material partnership within 90 days.